Original ArticleDonor mesenchymal stem cell linetics after transamniotic stem cell therapy (TRASCET) for experimental spina bifida
Section snippets
Methods
This study was approved by the Boston Children's Hospital Institutional Animal Care and Use Committee under protocol #15–07-2951R.
Results
Overall fetal survival was 92% (132/144) and comparable between the groups that received cells (90%; 70/78), or luciferase alone (94%; 62/66). Among surviving fetuses, 60 (45%) had a neural tube defect, consisting of either an isolated spina bifida (54; 90%), or spina bifida associated with exencephaly (6; 10%).
Among survivors receiving intra-amniotic injections of labeled afMSCs (n = 31), donor afMSCs were identified solely in the placenta, umbilical cord, spleen, bone marrow, hip bones, defect,
Discussion
Prenatal repair of spina bifida has long been validated clinically and is now standard of care [10]. At the same time, it is not a cure and is justifiable only in a relatively limited patient cohort, as per rather stringent stratification criteria of candidate maternal-fetal units. Furthermore, in addition to its inherent risks to the mother and fetus, fetal surgery is feasible only relatively late into the pathophysiological process of this disease. Should it eventually prove clinically
Acknowledgement
This work was supported by the Kevin and Kate McCarey Fund for Surgical Research at Boston Children's Hospital. H.F.S. was supported by a Joshua Ryan Rappaport Fellowship from the Department of Surgery at Boston Children's Hospital.
References (13)
- et al.
Partial or complete coverage of experimental spina bifida by simple intra-amniotic injection of concentrated amniotic mesenchymal stem cells
J Pediatr Surg
(2015) - et al.
Trans-amniotic stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifida
J Pediatr Surg
(2015) - et al.
A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifida
J Pediatr Surg
(2016) - et al.
The amniotic fluid as a source of cells for fetal tissue engineering
J Pediatr Surg
(2001) - et al.
Retinoic acid induced myelomeningocele in fetal rats: characterization by histopathological analysis and magnetic resonance imaging
Exp Neurol
(2005) - et al.
Fetal bone marrow homing of donor mesenchymal stem cells after transamniotic stem cell therapy (TRASCET)
J Pediatr Surg
(2018)
Cited by (27)
Bidirectional Feto-Maternal Traffic of Donor Mesenchymal Stem Cells Following Transamniotic Stem Cell Therapy (TRASCET)
2024, Journal of Pediatric SurgeryTransamniotic stem cell therapy (TRASCET): An emerging minimally invasive strategy for intrauterine stem cell delivery
2023, Seminars in PerinatologyBrain protection by transamniotic stem cell therapy (TRASCET) in a model of intrauterine growth restriction (IUGR)
2023, Journal of Pediatric SurgeryRouting pathway of syngeneic donor hematopoietic stem cells after simple intra-amniotic delivery
2022, Journal of Pediatric SurgeryPassive perinatal immunotherapy via transamniotic antibody delivery
2022, Journal of Pediatric SurgeryCitation Excerpt :However, delivery of immunoglobulins directly to the fetus is invasive and morbid, while indirect delivery via the mother is limited by poor and selective placental transfer. It has been recently been shown that the amniotic fluid/cavity constitutes a practicable access window to the fetal circulation, at least for the administration of select fetal stem cells [4–6]. In this study, we sought to determine whether the amniotic cavity/fluid could also be a route of administration of therapeutic antibodies to the fetus and neonate.
In utero treatment of myelomeningocele with allogenic umbilical cord-derived mesenchymal stromal cells in an ovine model
2022, Current Research in Translational Medicine